Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ? - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Transfusion Clinique et Biologique Année : 2015

[Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants?].

Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ?

Résumé

Until 1990, congenital hemorrhagic disorders were treated by plasma-derived concentrates. The first recombinant drug, recombinant factor VIII was available after this date and few years later recombinant factor IX could also be proposed to patients. The evolution of market share in France was different between these two drugs: while recombinant factor VIII took a large place in hemophilia A treatment (85%), plasma-derived factor IX represent 50% of the French market. In the next years, the arrival of long-acting antihemophilic factors may lead to the dramatically reduce the amount of plasma-derived antihemophilic factors used to treat hemophilia. For rare bleeding coagulation disorders, plasma-derived concentrates are still widely used, while they are the only concentrates available in most diseases. This situation is unlikely to evolve significantly in the next years.
Fichier non déposé

Dates et versions

hal-02004231 , version 1 (01-02-2019)

Identifiants

Citer

J.-F. Schved. Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ?. Transfusion Clinique et Biologique, 2015, 22 (3), pp.85-89. ⟨10.1016/j.tracli.2015.03.006⟩. ⟨hal-02004231⟩

Collections

UNIV-MONTPELLIER
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More